Your browser doesn't support javascript.
loading
[Latest advances in the development of tuberculosis vaccines in global clinical trials: a review].
Zhou, F; Zhang, Y; Zhang, D.
Affiliation
  • Zhou F; Department of Tropical Diseases, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
  • Zhang Y; Co-first authors.
  • Zhang D; Department of Tropical Diseases, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi ; 36(2): 201-206, 2024 Mar 29.
Article in Zh | MEDLINE | ID: mdl-38857967
ABSTRACT
Tuberculosis (TB) remains one of the biggest infectious killers worldwide. Vaccine is the most satisfactory tool for prevention of TB; however, Bacillus Calmette-Guérin (BCG), the widely used vaccine in clinical for the prevention of TB, has limitations in protective effects. Development of novel TB vaccines is therefore of urgent need. Currently, there are 15 novel TB vaccine candidates in clinical trials, including live-attenuated vaccines, inactivated vaccines, subunit vaccines and viral-vectored vaccines, which open the door for the ultimate target of the End TB Strategy. This review summarizes the latest advances in the development of TB vaccines in global clinical trials, so as to provide insights into TB control.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Clinical Trials as Topic / Tuberculosis Vaccines Limits: Humans Language: Zh Journal: Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi Year: 2024 Document type: Article Affiliation country: China Country of publication: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Clinical Trials as Topic / Tuberculosis Vaccines Limits: Humans Language: Zh Journal: Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi Year: 2024 Document type: Article Affiliation country: China Country of publication: China